证券代码：300723 证券简称：一品红 公告编号：2025-037 一品红药业集团股份有限公司 关于全资子公司获得酮咯酸氨丁三醇注射液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于酮咯酸氨丁三醇 注射液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：酮咯酸氨丁三醇注射液 英文名/拉丁名：Ketorolac Trometamol Injection 主要成份：酮咯酸氨丁三醇 剂 型：注射剂 包装规格：10 支/盒 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 上市许可持有人：广州一品红制药有限公司 上市许可持有人地址：广州市经济技术开发区东区东博路 6 号 生产企业：河北凯威制药有限 ...

Core Viewpoint - The company Yipinhong (300723.SZ) announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% from May 19 to May 21, indicating unusual trading activity [1] Summary by Relevant Sections - **Stock Performance** - The stock price of Yipinhong saw a cumulative increase of over 30% during the specified trading days, which is classified as an abnormal fluctuation in stock trading [1] - **Product Development** - The company is collaborating on the innovative drug AR882, which still requires Phase III clinical trials both domestically and internationally, as well as approval from drug regulatory authorities before it can be marketed [1] - The timeline for regulatory approval and market launch of AR882 remains uncertain, as it has not yet achieved market sales and has not generated any revenue for the company [1]

证券代码：300723 证券简称：一品红 公告编号：2025-036 一品红药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、一品红药业集团股份有限公司（以下简称："公司"）2025 年 5 月 19 日、 2025 年 5 月 20 日、2025 年 5 月 21 日连续三个交易日收盘价格涨幅偏离值累计 超过 30%，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常波 动的情况。 2、公司于 2025 年 4 月 25 日披露《2024 年年度报告》和《2025 年第一季度 报告》，公司 2024 年度归属于上市公司股东的净利润-54,003.90 万元，归属于 上市公司股东的扣除非经常性损益后的净利润-28,893.63 万元（经审计）；公司 2025 年第一季度归属于上市公司股东的净利润 5,658.85 万元，归属于上市公司 股东的扣除非经常性损益后的净利润 1,518.94 万元（未经审计）。敬请广大投资 者基于专业和理性的判断进行投资决策，注意投资风险。 3、根据相关规定，公司 ...

Group 1 - Sanofi's innovative drug company, Sangfor, has granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, marking a significant milestone for domestic pharmaceutical companies in entering the global market [1] - Pfizer will pay a non-refundable and non-offsettable upfront payment of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales revenue share based on product sales in authorized regions [1] Group 2 - Yipinhong announced the acquisition of a 15.25% stake in its subsidiary Guangzhou Rui'an Bo from minority shareholder Arthrosi for $6.8 million (approximately 49 million RMB) to enhance its market rights for the innovative drug AR882 in China and to promote efficient research and rapid market entry [2] - The transaction's pricing and the ongoing technical support from Arthrosi will be closely monitored for future clinical progress and market access efficiency [2] Group 3 - Huasheng Technology received an administrative regulatory measure from the Sichuan Securities Regulatory Bureau, which ordered the company to rectify issues related to accounting irregularities, non-operating fund occupation, and inadequate internal controls [3] - The regulatory action highlights weaknesses in the company's governance structure and compliance awareness, potentially affecting the rights of minority investors [3] Group 4 - Fosun Pharma announced the resignation of Rong Yang, CEO of its U.S. subsidiary, due to personal reasons, raising concerns about the continuity of leadership and strategic direction in the critical U.S. market for innovative drug commercialization [4] - The company is currently expanding its capabilities in the U.S. for both generic and innovative drug registration and commercialization [4]

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]

A股今日（5月20日）全线上扬，市场整体活跃，成交量有所放大；港股亦走高，两大股指均涨超 1%。 中信证券表示，海外订单稳健增长、鸡肉成本下行、人民币贬值、国产宠粮自主品牌整体增长提速、国货 龙头盈利能力持续提升等背景下，2024年、2025年一季度宠物板块业绩持续新高。展望后续，预计海外 需求稳健，国内市场国货替代持续，2025年宠物板块业绩有望持续增长。宠物经济是稀缺赛道，需求韧 性强，国内市场目前仍处"大行业、小龙头"阶段，龙头集中程度有望进一步提升，看好龙头通过产品创 新、品牌和渠道建设不断提升市场份额。 具体来看，A股三大股指盘中发力拉升，创业板指一度涨超1%。截至收盘，沪指涨0.38%报3380.48 点，深证成指涨0.77%报10249.17点，创业板指涨0.77%报2048.46点，北证50指数涨1.22%，沪深北 三市合计成交12114亿元，较昨日（5月19日）增加923亿元。 场 内 超 3800 股 飘 红 ， 宠 物 经 济 概 念 爆 发 ， 天 元 宠 物 （ 301335 ） 20% 涨 停 创 出 新 高 ， 路 斯 股 份 （832419）一度涨停亦创新高；合成生物概念再度活 ...

Group 1 - The pharmaceutical sector experienced a significant rise, with innovative drugs and weight-loss drug concepts performing particularly well, highlighted by Yipin Hong's 20% surge to a new high [2] - The recent executive order signed by U.S. President Trump mandates pharmaceutical companies to sell drugs in the U.S. at prices comparable to those in developed countries, although the implementation faces legal challenges and uncertainties [2] - Long-term implications suggest that if the current international drug pricing gradient is disrupted, it may prompt global pharmaceutical companies to adjust their pricing strategies, potentially positioning China as a low-cost research and production center [2] Group 2 - The U.S. pharmaceutical system involves multiple stakeholders, including distributors, PBMs, and insurers, making it challenging to implement price reductions effectively [3] - If Trump enforces the executive order to lower drug prices, U.S. pharmaceutical companies may experience compressed profit margins, which could have profound effects on the global pharmaceutical supply chain [3] - Domestic companies may see a reshaping of valuations and opportunities for innovative drugs in international markets, with an increased reliance on CXO companies for cost control [3]

Group 1 - The core viewpoint of the announcement is that the Supervisory Board of Yipinhong Pharmaceutical Group Co., Ltd. has approved the transfer of minority shares from a controlling subsidiary, which aligns with the company's development strategy and complies with legal regulations [1][2] - The Supervisory Board meeting was held on May 16, 2025, with all three supervisors present, and the procedures followed legal and regulatory requirements [1] - The board unanimously agreed to use up to RMB 500 million of idle self-owned funds for cash management, focusing on safe and liquid financial products, pending approval from the shareholders' meeting [2]

证券代码：300723 证券简称：一品红 公告编号： 2025-035 一品红药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召 开了第四届董事会第九次会议和第四届监事会第九次会议，审议通过了《关于公 司使用部分闲置自有资金进行现金管理的议案》，同意公司及子公司使用额度不 超过人民币 50,000 万元（含本数）的暂时闲置自有资金进行现金管理，授权期 限自股东大会审议通过之日起一年内可滚动使用，并授权公司管理层负责办理实 施。 一、使用部分闲置自有资金进行现金管理的基本情况 （一）投资目的 为了进一步提高资金使用效率，在确保不影响公司及子公司正常经营以及确 保流动性和资金安全的前提下，公司及子公司使用部分闲置自有资金进行现金管 理。 （二）投资品种 为控制风险，投资购买的理财品种为安全性高、流动性好、风险等级较低的 理财产品，包括但不限于结构性存款、协定存款、通知存款、定期存款、大额存 单、收益凭证等理财产品。 （三）决议有效期 自公司股东大会审议通过之日起一 ...

证券代码：300723 证券简称：一品红 公告编号：2025-035 一品红药业集团股份有限公司 关于公司使用部分闲置自有资金进行现金管理的公告 本次现金管理的资金来源为公司及子公司暂时闲置的自有资金，额度不超过 人民币 50,000 万元（含本数），在上述额度内资金可以在决议有效期内进行滚动 使用。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召 开了第四届董事会第九次会议和第四届监事会第九次会议，审议通过了《关于公 司使用部分闲置自有资金进行现金管理的议案》，同意公司及子公司使用额度不 超过人民币 50,000 万元（含本数）的暂时闲置自有资金进行现金管理，授权期 限自股东大会审议通过之日起一年内可滚动使用，并授权公司管理层负责办理实 施。 一、使用部分闲置自有资金进行现金管理的基本情况 （一）投资目的 为了进一步提高资金使用效率，在确保不影响公司及子公司正常经营以及确 保流动性和资金安全的前提下，公司及子公司使用部分闲置自有资金进行现金管 理。 （二）投资品种 为控制风险 ...